Threshold Pharmaceuticals

0.5420

+0.04438.90%

Volume:1.42M

Turnover:766.38K

Market Cap:38.79M

PE:-1.59

High:0.5500

Open:0.5000

Low:0.4701

Close:0.4977

52wk High:1.48

52wk Low:0.3500

Shares:71.56M

Float Shares:59.86M

Volume Ratio:52.52

T/O Rate:2.37%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3400

ROE:--

ROA:--

PB:2.53

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Threshold Pharmaceuticals

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.thresholdpharm.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Threshold Pharmaceuticals, Inc. discovers and develops therapeutic agents that target tumor cells for the treatment of cancer patients in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and advanced pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma; and Phase I/II clinical trials for multiple myeloma. The company is also involved in the study of evofosfamide in investigator sponsored trials, including Phase I/II clinical trials for glioblastoma; Phase I clinical trials for advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; Phase I clinical trials for advanced solid tumors; and Phase I/II clinical trials for advanced kidney cancer or liver cancer. In addition, it engages in developing Tarloxotinib, a hypoxia-activated EGFR tyrosine kinase inhibitor, which is in two Phase II clinical trials for patients with advanced non-squamous non-small cell lung cancer, as well as patients with squamous cell carcinomas of the head, neck, or skin; and [18F]-HX4, an investigational PET imaging agent for hypoxia. The company has a license agreement with Merck KGaA to co-develop and commercialize evofosfamide; license agreement with Auckland UniServices Ltd. for the development program based on Tarloxotinib; and license agreement with Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. It also has a collaboration with the National Cancer Institute to study TH-3424, a drug candidate for the treatment of cancer. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.